프로카인아미드의 HPLC 분석법 및 한국인에서의 약동학적 특징

HPLC Determination and Pharmacokinetic Profile of Procainamidein Korean Subjects

Procainamide is the drug of second choice (after lidocaine) in most coronary care units for the treatment of sustained ventricular arrhythmias associated with acute myocardial infarction. The purpose of this study was to develop the efficient assay method of procainamide in human plasma and to assess the pharmacokinetic profile of procainamide in healthy Korean volunteers. The pharmacokinetics of procainamide administered orally was evaluated after a dose of 250 mg. Procainamide in plasma was assayed using a specific HPLC method with UV absorbance at 275nm. AUC was 4.58±0.90 μg/ml.hr, Cmax 1.34±0.39 μg/ml, Tmax 1.06±0.34 hr and half-life 3.07±0.34 hr. Tmax was slightly shorter than that in Caucasian (1~2hr), whereas the half-life was similar to that in Caucasian (2.5~4.1 hr).